TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
TScan Therapeutics (Nasdaq: TCRX) will present in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics (Nasdaq: TCRX) will present in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00 p.m. ET. A live webcast will stream at the company’s Events and Presentations page and an archived replay will be available for 90 days.
Details
News Market Reaction – TCRX
On Apr 8, the day this news came out, TCRX closed 0.93% below the previous close.
Data tracked by StockTitan Argus for the Apr 8 session.
Key Figures
- Conference date
- April 15, 2026
- Needham Virtual Healthcare Conference fireside chat
- Conference time
- 3:00 p.m. Eastern Time
- Scheduled start time of fireside chat
- Replay availability
- 90 days
- Archived webcast replay on company website
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference iteration
Historical Context
-
Q4/FY25 results, IND clearances, and cash runway into H2 2027.
-
Cohort C completion in ALLOHA™ and FDA IND clearance for TSC-102.
-
TD Cowen conference fireside chat with webcast and 90-day replay.
-
Positive ALLOHA™ Phase 1 TSC-101 data and FDA-agreed pivotal design.
-
Virtual KOL event on ALLOHA™ data, manufacturing, and pivotal trial plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
t cell receptor medical
tcr-t medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time.
A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company is in early stages of developing methods for in vivo engineering to treat solid tumors. The Company is also applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.
Investor and Media Contact
Caileigh Dougherty
857-399-9890
ir@tscan.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.